Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP)‘s stock had its “buy” rating reissued by analysts at Noble Financial in a research note issued on Friday. They presently have a $19.00 price objective on the biopharmaceutical company’s stock. Noble Financial’s target price points to a potential upside of 114.69% from the company’s current price.

A number of other equities research analysts have also recently commented on CRBP. Aegis restated a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a research note on Sunday, August 21st. Cantor Fitzgerald reiterated a “buy” rating and set a $17.00 price objective on shares of Corbus Pharmaceuticals Holdings in a research report on Wednesday, October 26th.

Shares of Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) opened at 8.85 on Friday. The company’s market capitalization is $387.17 million. The company’s 50-day moving average is $7.14 and its 200-day moving average is $4.41. Corbus Pharmaceuticals Holdings has a 12-month low of $1.01 and a 12-month high of $10.78.

In related news, insider Barbara White acquired 38,000 shares of Corbus Pharmaceuticals Holdings stock in a transaction dated Wednesday, August 17th. The shares were purchased at an average price of $3.15 per share, for a total transaction of $119,700.00. Following the completion of the transaction, the insider now directly owns 161,067 shares in the company, valued at approximately $507,361.05. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Sean F. Moran acquired 148,960 shares of Corbus Pharmaceuticals Holdings stock in a transaction dated Thursday, August 18th. The shares were bought at an average price of $3.32 per share, for a total transaction of $494,547.20. Following the transaction, the chief financial officer now owns 216,410 shares of the company’s stock, valued at $718,481.20. The disclosure for this purchase can be found here. Insiders own 11.60% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Morgan Stanley raised its position in Corbus Pharmaceuticals Holdings by 12.4% in the third quarter. Morgan Stanley now owns 29,909 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 3,300 shares during the period. Northern Trust Corp raised its position in Corbus Pharmaceuticals Holdings by 41.0% in the third quarter. Northern Trust Corp now owns 45,436 shares of the biopharmaceutical company’s stock worth $309,000 after buying an additional 13,222 shares during the period. Milestone Group Inc. acquired a new position in Corbus Pharmaceuticals Holdings during the third quarter worth $102,000. Bank of New York Mellon Corp acquired a new position in Corbus Pharmaceuticals Holdings during the third quarter worth $155,000. Finally, BlackRock Institutional Trust Company N.A. raised its position in Corbus Pharmaceuticals Holdings by 14.3% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 216,139 shares of the biopharmaceutical company’s stock worth $1,468,000 after buying an additional 27,000 shares during the period. Hedge funds and other institutional investors own 25.39% of the company’s stock.

Corbus Pharmaceuticals Holdings Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases.

5 Day Chart for NASDAQ:CRBP

Receive News & Stock Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related stocks with our FREE daily email newsletter.